新規診断急性骨髄性白血病におけるCPX-351(リポソーム化シタラビンおよびダウノルビシン)とベネトクラクス+低メチル化剤療法との比較:メイヨークリニック患者600名を対象とした後向き比較研究|血液がんジャーナル – ネイチャー
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent the…
記事本文
The comparative value of liposomal cytarabine/daunorubicin (CPX-351) versus venetoclax plus a hypomethylating agent (Ven-HMA) in the frontline treatment of older adults with primary (de novo) or secondary acute myeloid leukemia (AML) remains uncertain. In the current study, we retrospectively examined outcomes of 600 patients with newly diagnosed AML treated with CPX-351 (N = 112) or Ven-HMA (N = 488). AML subtypes included de novo (N = 277,46%), post-myelodysplastic syndrome (post-MDS, N = 114,19%), post-myeloproliferative neoplasm (post-MPN, N = 70,12%), post-MDS/MPN (N = 36,6%), and t-AML (N = 103,17%). Patients receiving CPX-351 were younger (median 65 vs. 73 years; p
この記事に関連する商品
記事のタイトル、要約、本文から関連性の高い商品を自動的に表示しています。
よくある質問
Which products are related to this article?
The system matched these relevant products from the article content: ルシウス・ヴェネトクラクス – オンラインで購入、VECLADX ベネトクラクス 100mg、ルシウス・クイザルチニブ – オンラインで購入、ルシウス・アナグレリド – オンライン購入.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.